Sunday October 22, 2017
PennyStockReporting.com

Penny Stocks To Watch – DARA pt. 2

A.J. Watkinson May 28, 2014 Penny Stocks to Watch No Comments
Penny Stocks To Watch – DARA pt. 2

Hey there Penny Stock Reporting readers -

Today, DARA Bioscience stock shot up by more than 98%! 

The insane part of it is there has been no material news release associated with the pop in the stock.  No earnings, no material disclosures, no pr newswire release… nothing!

And it wasn’t a result of the short interest either.   With just 12.4% of the float being held short as of last report, we’re likely not looking at a short spike either.

Regardless, below you’ll find the text of the article I published back in February.  And all of it still holds true today…

————————– Originally published February 2014 ——————————–

Sometimes the best investments are penny stocks you’ve never heard of.  And I’d be willing to bet there are quite a few under your radar- given the literally thousands upon thousands of penny stocks to buy!

We’re focusing on a penny stock to watch called DARA Bioscience (DARA)…

DARA is an oncology-related pharmaceutical company working to provide healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments.

The stock saw a nice pop yesterday of more than 23%!

So why the big move?

Dara Bioscience just announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to KRN5500 for the parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy.  KRN5500 is a novel, non-opioid, non-narcotic intravenous product currently in Phase 2 clinical development.

Basically, this drug will give pain relief to some folks with a virtually untreatable level of pain that has resulted from aggressive chemotherapy.   And the fact the FDA has allowed this drug Orphan Drug Designation will allow a much faster track for DARA to bring it to market!

If you’re not aware, an orphan drug is one that has been developed specifically to treat a rare medical condition.  In the US it is easier to win marketing approval for an orphan drug than all others coming before FDA approval.

Additionally, there may be other financial incentives, such as extended exclusivity periods which are intended to encourage the development of drugs which might otherwise lack profitability.

That’s going to mean faster relief for patients, and also a quicker return for investors… making it a win-win situation.

DARA also holds exclusive U.S. marketing rights to Soltamox® (tamoxifen citrate) oral solution, which is the only liquid form of tamoxifen, used for the treatment of breast cancer.

The latest news from DARA doesn’t represent a new blockbuster “must have” drug with hopes of massive profit potential, but it does bode well that this little drug company may just turn a profit on their latest R&D sooner rather than later.

And that’s certainly makes for a penny stock to watch

Keeping you one step ahead,

Signature

 

 

A.J. Watkinson

 

 

Summary
Article Name
DARA- Penny Stocks To Watch
Author
Description
Here’s a penny stock to watch that could become a massive winner…

Like this Article? Share it!

About The Author

A.J cut his teeth while working for more than 12 years on the corporate side of the financial services industry in the suburbs of New York City. In addition, A.J. has successfully traded stocks, options and currencies as an independent trader since the late 90's. Eventually A.J. moved out of the "rat race", landing in North Scottsdale, Arizona. During the past few years, he's worked as the editor of a number of high profile financial newsletters. In this role, he's run trading services for penny stocks, options, currencies, ETFs, and FOREX. While under his direction, each of these trading services had turned in positive performance... something very rare in the financial newsletter industry. In addition, he's been a regular contributor to a number of financial websites- writing under multiple pen names. A.J.'s current goal is to share his real world experiences and success (and failures) in the various financial markets to help others not only make money- but avoid losing it. It's this vision and passion that has led A.J. to launch pennystockreporting.com. Most of all, A.J. hopes to keep the little guy from getting caught up in the highly unscrupulous penny stock pump and dump scene.

Leave A Response

You must be logged in to post a comment.